2 Stocks Down More Than 90% That Still Aren’t Worth Buying
Now, it’s worth noting Stock Advisor’s total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don’t miss out on the latest top 10 list, available when you …
Neural Therapeutics Acquires Stake in German CBD Retailer Hanf.com
An announcement from Neural Therapeutics Inc. ( ($TSE:NURL) ) is now available. Neural Therapeutics Inc. has completed the acquisition of a 30.75% …
CenTex CBD is closing their doors amidst uncertainty and political debate
The ongoing battle to ban THC in Texas led to their decision.
Cardiol Therapeutics’ stock down 20% on Phase II CardiolRx failure
CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.
CBD Life Sciences Inc. (CBDL) Announces National Expansion into Las Vegas Resorts & Hotels
Las Vegas CBD market projected to surpass $550 million by 2026, driven by tourism, retail, and wellness integration SCOTTSDALE, AZ / ACCESS Newswire / August 5, 2025 / CBD Life Sciences Inc. (OTC:CBDL …
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
CBD Life Sciences Inc. (CBDL) Huge Momentum Following NECANN New Jersey 2025
The U.S. marijuana dispensary market is projected to generate over $31.8 billion annually by 2025, creating multi-million-dollar opportunities for CBDL through dispensary partnerships and large-scale …
Sydney to see eight new office projects until Q4 2027
These will yield nearly 200,000sqm of stock. There were three office completions in Sydney totalling 46,900 sqm over the second quarter and no withdrawals in the CBD, according to a JLL report. There …
Innocan Pharma’s CBD Technology Gains Traction at PAINWeek Conference
InnoCan Pharma ( ($TSE:INNO) ) has provided an update. Innocan Pharma’s presentation on its Liposomal Synthetic CBD Technology at the PAINWeek …
Elixinol Wellness to Quote 46.8 Million Securities on ASX
An announcement from Elixinol Wellness ( ($AU:EXL) ) is now available. Elixinol Wellness Limited has announced the quotation of 46,800,000 …
Why value investing has worked better outside the US
While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market capitalization outside the US. Rather, value stocks in emerging markets …
CENTR Brands Corp. Closes $150,000 Private Placement to Bolster Financial Position
CENTR Brands ( ($TSE:CNTR) ) just unveiled an update. CENTR Brands Corp. has successfully closed a non-brokered private placement of unsecured …
Tilray Medical Study Finds Oral THC:CBD Extract Offers Faster, Higher Bioavailability
Tilray Brands Inc. (NASDAQ:TLRY) is one of the best penny stocks under $1 to buy now. On June 26, Tilray Brands, through its medical division, Tilray Medical, published a new scientific study on the …
InnoCan Pharma Stock: Nasdaq Listing Filing Signals Major Leap
InnoCan Pharma has officially filed registration documents with the SEC for a Nasdaq listing on July 23, 2025, marking a transformative moment for the Israeli-Canadian biotech company. The …
Cronos Group Inc. (CRON): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion …
Recent Comments